var data={"title":"Aflibercept (ziv-aflibercept) (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aflibercept (ziv-aflibercept) (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/517410?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aflibercept-ziv-aflibercept-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aflibercept (ziv-aflibercept) (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14787449\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemorrhage:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe and sometimes fatal hemorrhage, including GI hemorrhage, has been reported in patients who have received ziv-aflibercept in combination with irinotecan, leucovorin, and 5-fluorouracil (FOLFIRI). Monitor patients for signs and symptoms of GI bleeding and other severe bleeding. Do not administer ziv-aflibercept to patients with severe hemorrhage.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">GI perforation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">GI perforation, including fatal GI perforation, can occur in patients receiving ziv-aflibercept. Discontinue ziv-aflibercept therapy in patients who experience GI perforation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Compromised wound healing:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe compromised wound healing can occur in patients receiving ziv-aflibercept with irinotecan, leucovorin, and 5-fluorouracil. Discontinue ziv-aflibercept in patients with compromised wound healing. Suspend ziv-aflibercept for at least 4 weeks prior to elective surgery, and do not resume ziv-aflibercept for at least 4 weeks following major surgery and until the surgical wound is fully healed.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14933262\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zaltrap</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14787442\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent;</li>\n      <li>\n        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857084\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Colorectal cancer, metastatic:</b> IV: 4 mg/kg every 2 weeks (in combination with fluorouracil, leucovorin, and irinotecan [FOLFIRI]), continue until disease progression or unacceptable toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857085\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857087\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, need for adjustment is not likely because  exposure in patients with mild, moderate, and severe impairment was similar to that of patients with normal renal function. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857088\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Mild (total bilirubin &gt;1 to 1.5 times ULN) to moderate (total bilirubin &gt;1.5 to 3 times ULN) impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, need for adjustment is not likely because exposure was similar to that of patients with normal hepatic function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Severe impairment (total bilirubin &gt;3 times ULN): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (no data available).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857086\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Arterial thrombotic events:</i> Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Fistula formation:</i> Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Gastrointestinal perforation:</i> Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Hemorrhage, severe: </i>Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Hypertension:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Recurrent or severe hypertension: Temporarily withhold treatment until controlled and then resume with a permanent dose reduction to 2 mg/kg every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Hypertensive crisis or hypertensive encephalopathy: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Neutropenia:</i> Temporarily withhold treatment until ANC is &ge;1500/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Renal effects:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Proteinuria (&ge;2 g/24 hours): Temporarily withhold treatment until proteinuria &lt;2 g/24 hours and then resume at previous dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Recurrent proteinuria: Temporarily withhold treatment until proteinuria &lt;2 g/24 hours and then resume with a permanent dose reduction to 2 mg/kg every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Nephrotic syndrome or thrombotic microangiopathy: Discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Reversible posterior leukoencephalopathy syndrome (RPLS): </i>Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Surgery/wound healing impairment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Elective surgery: Temporarily withhold treatment for at least 4 weeks prior to elective surgery; do not resume until at least 4 weeks after major surgery AND until wound is fully healed; for minor surgery (eg, biopsy, central venous port placement, tooth extraction), may be resumed after wound is fully healed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Wound healing impaired: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> For toxicities related to FOLFIRI, refer to individual Fluorouracil or Irinotecan monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14934219\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zaltrap: 100 mg/4 mL (4 mL); 200 mg/8 mL (8 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857062\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857089\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 1 hour. Do not administer as an IV push or bolus. Administer prior to any FOLFIRI component. Do not administer other medications through the same intravenous line.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infuse via a 0.2 micron polyethersulfone filter; do not use filters made of polyvinylidene fluoride (PVDF) or nylon. Administer with one of the following types of infusion sets: Polyvinyl chloride (PVC) containing DEHP, DEHP-free PVC containing trioctyl-trimellitate (TOTM), polypropylene, polyethylene lined PVC, or polyurethane.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132723\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14787443\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Colorectal cancer, metastatic:</b> Treatment of metastatic colorectal cancer (in combination with fluorouracil, leucovorin, and irinotecan [FOLFIRI]) in patients who are resistant to or have progressed on an oxaliplatin-based regimen</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857061\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ziv-aflibercept may be confused with aflibercept </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14943700\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reactions reported in combination therapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (41%; grade 3: 19%; grade 4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (48%), voice disorder (25%; grades 3/4: &lt;1%), headache (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Palmar-plantar erythrodysesthesia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (32%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (69%; grades 3/4: 19%), stomatitis (50%), decreased appetite (32%), abdominal pain (27%), upper abdominal pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Proteinuria (62%, grades 3/4: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic: Leukopenia (78%; grades 3/4: 16%), neutropenia (67%; grades 3/4: 37%), thrombocytopenia (48%; grades 3/4: 3%), hemorrhage (38%; grades 3/4: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (62%), increased serum ALT (50%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (46%, grades 3/4: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (18%; grades 3/4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (28%; grades 3/4: &lt;1%), dyspnea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Venous thromboembolic events (9%), pulmonary embolism (5%), arterial thromboembolism (3%; grades 3/4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Reversible posterior encephalopathy syndrome (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperpigmentation (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (9%; grades 3/4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Hemorrhoids (6%), proctalgia (5%), rectal hemorrhage (5%; grades 3/4: &lt;1%), rectal pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (9%), nephrotic syndrome (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic: Febrile neutropenia (grades 3/4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Immunogenicity (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Neutropenic sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Oropharyngeal pain (8%), rhinorrhea (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fistula formation (2%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Intracranial hemorrhage (severe)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Pulmonary hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Osteonecrosis of the jaw, reduced ejection fracture, thrombotic thrombocytopenic purpura, wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857068\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857069\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: A higher incidence of neutropenia and complications due to neutropenia (neutropenic fever and infection) occurred in patients receiving ziv-aflibercept. Leukopenia and thrombocytopenia were also observed in clinical trials. Monitor CBC with differential (baseline and prior to each cycle); delay treatment until ANC is &ge;1,500/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea: Severe diarrhea and dehydration have been reported. The incidence of diarrhea is increased in patients &ge;65 years of age; monitor elderly patients closely for diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fistula formation: The risk for gastrointestinal (GI) and non-GI fistulas is increased with ziv-aflibercept. Fistula sites have included anal, enterovesical, enterocutaneous, colovaginal, and intestinal. Discontinue in patients who develop fistula.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal perforation: <b>[U.S. Boxed Warning]: Severe or fatal GI perforation is a possibility; discontinue ziv-aflibercept if GI perforation occurs.</b> Monitor for signs/symptoms of GI perforation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: The risk for hemorrhage is increased with ziv-aflibercept. <b>[U.S. Boxed Warning]: Severe and occasionally fatal hemorrhage, including GI bleeding, has been reported with ziv-aflibercept/FOLFIRI. Monitor for signs and symptoms of GI and other severe bleeding events. Do not administer to patients with severe hemorrhage. </b>Discontinue if severe hemorrhage develops. Hemorrhagic events have also included hematuria, postprocedural hemorrhage, intracranial hemorrhage, and pulmonary hemorrhage/hemoptysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: The risk for grades 3/4 hypertension is increased. Onset is generally within the first 2 treatment cycles. Monitor blood pressure every 2 weeks (more frequently if clinically indicated). Treat with appropriate antihypertensive therapy (may require adjustment of existing antihypertensives). Temporarily withhold treatment with uncontrolled hypertension; may reinitiate with permanent dose reduction when controlled. Discontinue for hypertensive crisis or encephalopathy. Patients with NYHA class III or IV heart failure were excluded from clinical trials.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria/nephrotic syndrome: Proteinuria, nephrotic syndrome, and thrombotic microangiopathy (TMA) have been associated with ziv-aflibercept. Evaluate for proteinuria during treatment with urine dipstick and/or urinary protein creatinine ratio (UPCR); if dipstick &ge;2+ for protein or UPCR &gt;1, obtain 24-hour urine collection. Withhold ziv-aflibercept for proteinuria &ge;2 g per 24 hours; for recurrent proteinuria, withhold treatment until &lt;2 g per 24 hours and then resume with permanent dose reduction. Discontinue treatment for nephrotic syndrome or TMA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reversible posterior leukoencephalopathy syndrome (RPLS): Cases of RPLS have been reported. Confirm diagnosis with MRI; discontinue ziv-aflibercept if verified. Symptoms generally resolve or improve within days, although persistent neurologic symptoms and death have been reported.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Arterial thrombotic events (ATE), including transient ischemic attack, cerebrovascular accidents, and angina have occurred. Discontinue ziv-aflibercept in patients who experience ATEs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing impairment: <b>[U.S. Boxed Warning]: Severely compromised wound healing may occur with ziv-aflibercept/FOLFIRI. Discontinue ziv-aflibercept with compromised wound healing. Withhold ziv-aflibercept at least 4 weeks prior to elective surgery. Do not resume ziv-aflibercept treatment until at least 4 weeks after major surgery AND until the surgical wound is completely healed.</b> For minor surgeries (eg, central venous access port placement, biopsy, or tooth extraction), ziv-aflibercept may be resumed or initiated as soon as the surgical wound is fully healed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Certain adverse events, such as diarrhea, dizziness, weakness, weight loss, and dehydration, occurred at a higher incidence in elderly compared to younger adults; monitor closely during treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14975299\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14975297\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86239&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857064\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857065\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies with doses providing systemic exposure equivalent to ~30% of a human dose. The incidence of fetal malformations increased with increasing doses. Patients (male and female) should use effective contraception during therapy and for at least 3 months following treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857067\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ziv-aflibercept is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision to be made whether to discontinue nursing or to discontinue aflibercept, taking  into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857092\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (baseline and prior to each cycle); urine protein (dipstick analysis and/or urinary protein creatinine ratio [UPCR], obtain 24-hour urine collection if dipstick &ge;2+ for protein or UPCR &gt;1); blood pressure (every 2 weeks; more frequently if clinically indicated); monitor for signs/symptoms of hemorrhage or GI perforation; monitor elderly patients closely for diarrhea and/or dehydration. Monitor wounds for healing impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857077\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Also known as VEGF-trap, ziv-aflibercept is a recombinant fusion protein which is comprised of portions of binding domains for vascular endothelial growth factor (VEGF) receptors 1 and 2, attached to the Fc portion of human IgG1. Ziv-aflibercept acts as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF) which prevent VEGF receptor binding/activation to their receptors (an action critical to angiogenesis), thus leading to antiangiogenesis and tumor regression. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14857079\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Half-life elimination: ~6 days (range: 4 to 7 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570448\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zaltrap Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/4 mL (4 mL): $1,920.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/8 mL (8 mL): $3,840.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26530952\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aflitiv (AU);</li>\n      <li>Lidaveg (AU);</li>\n      <li>Zaltrap (AE, AT, AU, BE, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, HK, HR, HU, IE, IL, IS, LT, LU, LV, MT, NL, NO, PT, QA, RO, SE, SG, SI, SK, TH, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allegra CJ, Lakomy R, Tabernero J, et al. Effects of Prior Bevacizumab (B) Use on Outcomes From the VELOUR Study: A Phase III Study of Aflibercept (Afl) and FOLFIRI in Patients (Pts) With Metastatic Colorectal Cancer (Mcrc) After Failure of an Oxaliplatin Regimen. <i>J Clin Oncol</i>. 2012;30(15s):3505 [abstract 3505 from ASCO 2012 Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaya A and Tse V. A Preclinical and Clinical Review of Aflibercept for the Management of Cancer. <i>Cancer Treat Rev</i>. 2012;38(5):484-493.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information/abstract-text/22264850/pubmed\" target=\"_blank\" id=\"22264850\">22264850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isambert N, Freyer G, Zanetta S, et al. Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination With Docetaxel in Patients With Advanced Solid Tumors. <i>Clin Cancer Res</i>. 2012;18(6):1743-1750.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information/abstract-text/22261804/pubmed\" target=\"_blank\" id=\"22261804\">22261804</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joulian F, Van Cutsem E, Iqbal SU, et al. Aflibercept versus Placebo in Combination With FOLFIRI in Previously Treated Metastatic Colorectal Cancer (Mcrc): Mean Overall Survival (OS) Estimation From a Phase III Trial (VELOUR). <i>J Clin Oncol</i>. 2012;30(15s):3602 [abstract 3602 from ASCO 2012 Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors. <i>J Clin Oncol</i>. 2010;28(2):207-214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information/abstract-text/19949018/pubmed\" target=\"_blank\" id=\"19949018\">19949018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tabernero J, Allegra CJ, Rougier PR, et al. Meta-Analysis of Anti-VEGF Class Adverse Events From Three Double-Blind (db) Placebo (pbo)-Controlled Phase III Trials With IV Aflibercept (Afl). <i>J Clin Oncol</i>. 2012;30(15s):3579 [abstract 3579 from ASCO 2012 Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. <i>Clin Cancer Res</i>. 2012;18(21):6023-6031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information/abstract-text/22977191/pubmed\" target=\"_blank\" id=\"22977191\">22977191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Cutsem E, Tabernero J, Lakomy R, et al, &quot;Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,&quot; <i>J Clin Oncol</i>, 2012, 30(28):3499-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aflibercept-ziv-aflibercept-systemic-drug-information/abstract-text/22949147/pubmed\" target=\"_blank\" id=\"22949147\">22949147</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaltrap (ziv-aflibercept) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; March 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86239 Version 86.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F14787449\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14933262\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14787442\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F14857084\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14857085\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14857087\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14857088\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F14857086\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F14934219\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F14857062\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F14857089\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132723\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14787443\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14857061\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F14943700\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F14857068\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F14857069\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F14975299\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F14975297\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F14857064\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14857065\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14857067\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14857092\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F14857077\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F14857079\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570448\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26530952\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/86239|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aflibercept-ziv-aflibercept-systemic-patient-drug-information\" class=\"drug drug_patient\">Aflibercept (ziv-aflibercept) (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}